In a remarkably short period of time, genomic medicine has led to exciting revelations that are transforming the way we are able to target and treat human disease on a fundamental level. The COVID-19 vaccines are perhaps one of the biggest success stories to date, having unequivocally demonstrated their efficacy and safety in the real world.
Genomic medicine offers a faster route for drug development, clinical diagnosis, and present new opportunities for gene-editing, immuno-oncology and personalized medicine applications. Among genomic medicine modalities, Ribonucleic Acid-Lipid Nanoparticle (RNA-LNP)-based therapeutics comprise a rapidly expanding category of drugs, which are being applied to solve areas of high medical need from infectious diseases to many other areas including cancer, rare diseases, and metabolic diseases.
The ability of mRNA-LNPs to induce the expression of nearly any protein with minimal changes to their chemical characteristics makes them an ideal platform to accelerate drug discovery, development and commercialization. Once the disease gene to target is identified, you can very rapidly find the DNA sequence—and in turn, the mRNA sequence—to use as the drug substance and have it manufactured. This unlocks a tremendous amount of innovation both in how we can treat disease and how medicine is distributed and administered as well. Learn about how fine-tuning the delivery of these genomic medicines to different tissues safely and effectively will continue to accelerate progress in the field.